Protective effect of A/H1N1 vaccination in immune-mediated disease-a prospectively controlled vaccination study

Rheumatology

Volumn 51, Issue 4, 2012, Pages 695-700

  Adler, Sabine ^a   Krivine, Anne ^b   Weix, Janine ^c   Rozenberg, Flore ^b   Launay, Odile ^b   Huesler, Juerg ^a   Guillevin, Loïc ^d   Villiger, Peter M ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b Hôpitaux de Paris ^*  (France)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d INSERM   (France)

Author keywords

H1N1; Influenza; Rheumatoid arthritis; Spondyloarthritis; Vaccination

Indexed keywords

ABATACEPT; CYCLOPHOSPHAMIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; INFLUENZA VACCINE; METHOTREXATE; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ANKYLOSING SPONDYLITIS; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRALGIA; ARTICLE; AUTOIMMUNE DISEASE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFECT; FEMALE; HEADACHE; HEMAGGLUTINATION INHIBITION TEST; HOSPITALIZATION; HUMAN; HYPERTHERMIA; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALAISE; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SEASONAL INFLUENZA; SEROCONVERSION; SHIVERING; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT RESPONSE; VASCULITIS;

ADULT; AGE FACTORS; AGED; ANTIBODIES, VIRAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; CASE-CONTROL STUDIES; CONNECTIVE TISSUE DISEASES; DISEASE PROGRESSION; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOSUPPRESSIVE AGENTS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RHEUMATIC DISEASES; SEX FACTORS; SPONDYLARTHRITIS; VACCINATION;

EID: 84858639592     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker389     Document Type: Article

References (20)

1. Doran M, Crowson C, Pond G. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002;46:2294-300.
2. Fessler B. Infectious diseases in lupus erythematosus: risk factors, management and prophylaxis. Best Pract Res Clin Rheum 2002;16:281-91.
3. Van Assen S, Agmon-Levin N, Elkayam O et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011;70:414-22.
4. Lanternier F, Henegar C, Mouthon L et al. Low influenza-vaccination rate among adults receiving immunosuppressive therapy for systemic inflammatory disease. Ann Rheum Dis 2008;67:1047.
5. Conti F, Rezai S, Valesini G. Vaccination and autoimmune rheumatic diseases. Autoimm Rev 2008;8:124-8.
6. Abu Shakra M, Press J, Buskila D et al. Influenza vaccination for patients with systemic lupus erythematosus: safety and immunogenicity issues. Autoimmun Rev 2007;6: 543-6.
7. Elkayam O. Safety and efficacy of vaccination against influenza in patients with rheumatoid arthritis. Clin Dev Immunol 2006;13:349-51.
8. Centers for Disease Control. Concepts and procedures for laboratory-based influenza surveillance, 1982. Atlanta Georgia: United States Public Health Service, Department of Health and Human Services, 1982.
9. Note for guidance on harmonization of requirements for influenza vaccines. Committee for Human Medicinal Products. http://www.ema.europa.eu/docs/en-GB/ document-library/Scientific-guideline/2009/09/ WC500003945.pdf.
10. Nauta J, de Bruijn I. The European CHMP criteria for influenza vaccine immunogenicity cannot be improved by the use of confidence intervals. Vaccine 2006;24:6643-4.
11. Skowronski D, Tweed S, De Serres G. Rapid decline of influenza-induced antibody in the elderly: is it real, or is it relevant? J Inf Dis 2008;197:490-502.
12. Kaine J, Kivitz A, Birbara C et al. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol 2007;34:272-9.
13. Fomin I, Caspi D, Levy V et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis 2006;65:191-4.
14. Kapetanovic M, Saxne T, Nilsson J et al. Influenza vaccination as model for testing immune modulation induced by anti-TNF and MTX therapy in rheumatoid arthritis patients. Rheumatology 2007;46: 608-11.
15. Holvast A, van Assen S, de Haan A et al. Studies of cell-mediated immune responses to influenza vaccination in systemic lupus erythematosus. Arhritis Rheum 2009;60: 2438-47.
16. Van Assen S, Holvast A, Benne C et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010;61:75-81.
17. Oren S, Mandelboim M, Braun-Moskovici Y et al. Vaccination against influenza in rheumatoid arthritis patients: the effect of rituximab on the humoral response. Ann Rheum Dis 2008;67:937-41.
18. Arad U, Tzadok S, Amir S et al. The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. Vaccine 2011;29:1643-8.
19. Gasparini R, Schioppa F, Lattanzi M et al. Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria TM) in adult elderly subjects. Int J Clin Pract 2010;64:432-8.
20. Gabay C, Bel M, Combescure C et al. Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine. Arthritis Rheum 2011;63: 1486-96.